查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553415

病毒惰性市场规模、份额、趋势分析报告：按产品和服务、按应用、按最终用途、按地区、按细分市场、预测，2024-2030 年

Viral Inactivation Market Size, Share & Trends Analysis Report By Products & Services (Kits & Reagents), By Application (Vaccines & Therapeutics), By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

病毒惰性市场成长与趋势

Grand View Research, Inc.最新报告显示，到2030年，全球病毒惰性市场规模预计将达到13.716亿美元，预测期内复合年增长率为11.4%。

主要成长动力包括製药和生物製药公司数量的增加、FDA 药品批准量的增加、生命科学产业的成长以及政府对新疗法和药物开发的资助增加。

由于公司数量的稳定增加、新药的推出和新药的发现，製药和生物製药行业正在经历显着的增长。随着世界范围内疾病数量的增加，世界各地对新药和改进治疗方法的需求也在增加。主要企业加大研发投入，加上寻找治疗疾病的新治疗方法的需求，正在促进并加速製药和生物製药公司的巨大成长。

本公司开发新药以增加健康益处。世界各地人们生活方式的改变和久坐生活方式的建立是导致需要药物和治疗方法治疗的慢性疾病增加的主要原因。据 FDA 称，2014 年核准了41 种核准，隔年批准了 45 种新药。这也有助于成长。

近年来，大量资金投入製药和生物技术产业。儘管私人公司为新药和新治疗方法的开发做出了重大贡献，但政府在新治疗方法研发上的支出也在增加。近年来，资金的增加也导致 FDA核准数量的增加。所有这些因素都促进了病毒惰性市场的巨大成长。

病毒灭活市场报告亮点

  • 由于消耗品使用增加，套件和试剂占最大份额。
  • 疫苗和治疗药物在应用中占据最大份额，并且由于生技药品需求的增加预计将快速增长。
  • 由于全球製药 CRO 的崛起，服务领域预计将以最快的速度成长。
  • 由于旨在遏制慢性病发病率的医疗改革以及主要企业和先进基础设施的存在，北美占据了最大的市场份额。
  • 由于医疗改革和製药业开拓的市场机会，预计亚太地区将在预测期内繁荣发展。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章 病毒灭活的变数、趋势和范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 病毒灭活分析工具
    • 波特的分析
    • PESTEL分析

第四章病毒灭活市场：按产品和服务分類的估计和趋势分析

  • 细分仪表板
  • 病毒灭活市场：2023年和2030年产品和服务的波动分析
  • 试剂套件和试剂
  • 系统及配件
  • 服务

第五章病毒灭活市场：按应用、估计和趋势分析

  • 细分仪表板
  • 病毒灭活市场：2023 年和 2030 年应用变化分析
  • 疫苗和治疗
  • 干细胞产品
  • 血液和血液製品
  • 组织/组织产品
  • 细胞和基因治疗

第六章 病毒灭活市场：依最终用途分类的估计与趋势分析

  • 细分仪表板
  • 病毒灭活市场：2023 年和 2030 年最终用途变化分析
  • 製药和生物技术公司
  • CRO
  • 学术研究所
  • 其他的

第七章 病毒灭活市场：区域估计与趋势分析

  • 2023 年和 2030 年按地区分類的病毒灭活份额，百万美元
  • 北美洲
    • 北美病毒灭活估计与预测，2018-2030
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 2018-2030 年欧洲病毒灭活估计与预测
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 2018-2030 年亚太地区病毒灭活估计与预测
    • 日本
    • 中国
    • 印度
    • 韩国
    • 泰国
  • 拉丁美洲
    • 2018-2030 年拉丁美洲病毒灭活估计与预测
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 2018-2030 年中东和非洲病毒灭活估计和预测
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Charles River Laboratories, Inc.
    • Clean Cells
    • Cytiva（Danaher Corporation）
    • Merck KGaA
    • Mettler Toledo
    • Parker Hannifin Corp
    • Rad Source Technologies Inc
    • Sartorius AG
    • Texcell SA
    • Vironova AB
简介目录
Product Code: GVR-1-68038-998-2

Viral Inactivation Market Growth & Trends:

The global viral inactivation market size is expected to reach USD 1,371.6 million by 2030, registering a CAGR of 11.4% during the forecast period, according to a new report by Grand View Research, Inc. Rise in the number of pharmaceutical and biopharmaceutical companies, increase in FDA drug approvals, growth of the life sciences industry, increase in government funding for novel therapies, and drug development are some of the major factors contributing to the growth.

Immense growth has been witnessed in the pharmaceutical and biopharmaceutical industry with a steady rise in the number of companies, drug launches, and new drug discoveries. With an increase in the number of diseases worldwide, the need for new & improved drugs and therapies has been witnessed on a global front. Increase in investment by top players in research and development coupled with the need to find new therapies for the treatment of diseases has contributed to immense growth of pharmaceutical and biopharmaceutical companies, thereby accelerating growth.

Newer drugs are being developed by companies to offer incremental health benefits. Changing lifestyle of people across the globe and adoption of sedentary living habits are primary reasons responsible for the increase in the number of chronic diseases that require drugs and therapies for treatment. According to the FDA, in the year 2014, 41 novel drugs were approved and 45 in the consequent year. This has also been contributing to growth.

Immense funding has been witnessed in the pharmaceutical and biotechnology industries in the recent years. It has been observed that private players are the major contributors for the development of new drugs and therapies, however, there has been increasing government spending on the research and development of new therapies. Increase in funding has also resulted in growth in number of FDA approvals over the recent years. All these factors have been contributing to the immense growth of the viral inactivation market.

Viral Inactivation Market Report Highlights:

  • Kits and reagents held the largest share owing to increasing usage of consumables
  • Vaccines and therapeutics held the largest share, on the basis of application, and is expected to be the fastest growing segment due to the increased demand for biologics
  • The services segment is anticipated to grow at the fastest rate due to increase in the number of pharmaceutical CROs globally
  • North America accounted for the largest share owing to presence of dominant players and availability of sophisticated infrastructure along with healthcare reforms to curb the incidence of chronic diseases
  • The Asia Pacific region is expected to flourish during the forecast period owing to healthcare reforms and untapped market opportunities in the pharmaceutical industry

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Viral Inactivation Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Viral Inactivation Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Viral Inactivation Market: Product & Services Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Viral Inactivation Market: Product & services Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Kits & Reagents
    • 4.3.1. Kits & Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Systems & Accessories
    • 4.4.1. Systems & Accessories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Services
    • 4.5.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Viral Inactivation Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Viral Inactivation Market: Application Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Vaccines & Therapeutics
    • 5.3.1. Vaccines & Therapeutics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Stem Cell Products
    • 5.4.1. Stem Cell Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Blood & Blood Products
    • 5.5.1. Blood & Blood Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Tissue/ Tissue Products
    • 5.6.1. Tissue/ Tissue Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Cellular and Gene Therapy
    • 5.7.1. Cellular and Gene Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Viral Inactivation Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Viral Inactivation Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Pharmaceutical & Biotechnological Companies
    • 6.3.1. Pharmaceutical & Biotechnological Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. CROs
    • 6.4.1. CROs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Academic and Research Institutes
    • 6.5.1. Academic and Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Viral Inactivation Market: Regional Estimates & Trend Analysis

  • 7.1. Viral Inactivation Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Sweden Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Thailand
      • 7.4.6.1. Thailand Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Viral Inactivation and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Viral Inactivation Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Charles River Laboratories, Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Clean Cells
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Cytiva (Danaher Corporation)
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Merck KGaA
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Mettler Toledo
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Parker Hannifin Corp
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Rad Source Technologies Inc
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Sartorius AG
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Texcell SA
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Vironova AB
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives